Home > Boards > US OTC > Biotechs >

Oncotelic Therapeutics Inc. (OTLC)

OTLC RSS Feed
Add OTLC Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Penny Stocks 2.0
Search This Board: 
Last Post: 5/10/2021 9:10:42 PM - Followers: 8 - Board type: Free - Posts Today: 0


Image result for oncotelic therapeutics
Reverse Merged with MATEON THERAPEUTICS Formally MATN

Oncotelic – Welcome to Oncotelic

$11 Billion Target Markets - 100+ Patent Applications - 2 Key Clinical Programs - 30+ Years Experience

Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after.

 

Oncotelic (formerly known as Mateon Therapeutics, Inc.) was created by the 2019 reverse merger with Oncotelic, which became a wholly owned subsidiary of Oncotelic, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has shown activity against SARS-CoV-2 and COVID-19. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.Oncotelic.com.

 

ARTIShield ™/ARTIVedaTM- an Ethnobiology Drug

Mateon is pursuing several avenues with respect to the development and commercialization of ARTIShield in the treatment of COVID-19. ARTIShield is Ayurveda - Dvipaantara Damanaka - and is labeled as a capsule containing Artemisia Powder 500mg. It is a demonstration of how Ethnobiology can be used to drive drug development against emerging pandemics.

The classical pharmaceutical regulatory pathways have failed to provide fast-track to treatment and vaccines. Government resources have concentrated on a few candidates most of which have failed. The Ayurvedic medicine route is proving to be an accelerated pathway to deploy a well-known, abundantly available and cost effective Ayurvedic medicine that is safe and being proven in-vitro and large-scale clinical trial to be effective.

ARTIShield /ARTIVeda - Commercialization in India

Mateon announced that ARTIShield /ARTIVeda has been approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) in India for the treatment of various symptoms including fever and inflammation, which can be associated with COVID-19. ARTIShield is in co-development with Windlas Biotech Pvt. Ltd., Mateon’s commercial partner for India and is designed to be a readily available and cost-effective agent to combat COVID-19. ARTIVeda is the tradename for India and ArtiShieldTM is the tradename for outside of India. Mateon expects sales will commence in India before year end.

ARTI-19 Multi-national Phase IV Trial, Currently in India

Mateon announced the enrollment of its first patient in a Phase IV study ARTI-19, “A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19”. This trial will compare the efficacy of oral doses with standard-of-care (SOC) versus SOC alone. This is a global study with India to contribute at least 300 patients to the total aggregate of 3000 patients. We expect preliminary top-line data for ARTI-19 sometime between Q420 and Q121.

About OT-101

OT-101 is an antisense against the host TGF-β protein required for viral replication and its overexpression likely to cause the wide range of clinical symptoms associated with COVID-19 including Kawasaki syndrome (Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3) and acute respiratory distress syndrome (ARDS) (Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in COVID-19. Clin. Invest. (Lond.) 2020; 10(2), 167-176. DOI: 10.4172/ Clinical-Investigation.1000166.).

TGF-β is elevated in COVID-19 (Xiong Y. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & infections 2020; 9:1, 761-770, DOI: 10.1080/22221751.2020.1747363. Agrati C. et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death & Differentiation 2020; https://doi.org/10.1038/s41418-020-0572-6.).

OT-101 is also being developed as an adjuvant for second generation COVID-19 vaccine. To avoid the two potential issues with 1st generation vaccine against COVID-19, we will be combining the 1st generation COVID-19 DNA vaccine with a TGF-β inhibitor (OT-101) to stimulate a strong immune response while suppressing the IgA class switching that could aggravate the disease through Kawasaki reaction- IgA vasculitis. The company is aggressively pursuing the development of this 2nd generation COVID-19 vaccine expecting that the 1st generation vaccines would not be fully effective and may not be sufficiently protective to counter the current pandemic.

The development of OT-101 is important given the failure of other drugs leaving dexamethasone as the only clinically proven effective drug against COVID-19.

OTLC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#376  Sticky Note $OTLC Monstrous 8-K Released AFTER HOURS Penny Stocks 2.0 05/08/21 02:11:59 PM
#248  Sticky Note $MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick 07/28/20 06:25:22 PM
#393   Oh ok..yea I don't know how it works MJAM2020 05/10/21 09:10:42 PM
#392   From what I understand for India, I could Birddogfishman 05/10/21 09:06:18 PM
#391   You are saying EUA for the U.S. correct? MJAM2020 05/10/21 09:00:37 PM
#390   I have been in for almost a year Birddogfishman 05/10/21 08:54:38 PM
#389   I grabbed some as well. These guys seem MJAM2020 05/10/21 08:38:43 PM
#388   thanks would like to be here for a saigai 05/10/21 08:22:13 PM
#387   Welcome aboard. Birddogfishman 05/10/21 08:18:47 PM
#386   thanks for all your sharing..im still not sure saigai 05/10/21 05:03:26 PM
#385   Another great day for investors. Penny Stocks 2.0 05/10/21 04:11:54 PM
#384   $OTLC MUST LISTEN 3:00 mark FDA Awarded Rare Penny Stocks 2.0 05/10/21 02:40:06 PM
#383   ok thanks i thought that was from a saigai 05/10/21 02:28:33 PM
#382   PIPELINE Cancer and viral infection treatments. ArtiVeda/ArtiShield – a Penny Stocks 2.0 05/10/21 02:19:37 PM
#381   i dont follow the tie in here saigai 05/10/21 02:18:39 PM
#380   And what.... Penny Stocks 2.0 05/10/21 01:53:24 PM
#379   and ..... saigai 05/10/21 01:24:45 PM
#378   Oxi4503/ Melanoma, Announced that the US FDA granted Penny Stocks 2.0 05/10/21 12:49:51 PM
#377   $OTLC .2895 A/H Monster $10,000,000 Purchase Agreement/NO SHORTING Penny Stocks 2.0 05/09/21 08:25:58 PM
#376   $OTLC Monstrous 8-K Released AFTER HOURS Penny Stocks 2.0 05/08/21 02:11:59 PM
#375   $OTLC My jaw is dropping every time I Penny Stocks 2.0 05/06/21 11:40:09 AM
#374   $OTLC MORE HUGE DD Bigger than you think! SPIN OFF Penny Stocks 2.0 05/06/21 11:12:42 AM
#373   The next $OCGN .17 to $18+ in a month. Penny Stocks 2.0 05/05/21 05:39:39 PM
#372   Overview   We are a clinical-stage biopharmaceutical developing drugs for Penny Stocks 2.0 05/05/21 03:48:40 PM
#371   Artemisinin for Treatment of COVID-19   Artemisinin derived from Chinese Penny Stocks 2.0 05/05/21 03:45:06 PM
#370   $OTLC HUGE TWEET Now that we ArtiVeda/Artemisinin is Penny Stocks 2.0 05/05/21 03:41:21 PM
#369   Our Strategy and Development Plan   We have been operating Penny Stocks 2.0 05/05/21 02:36:44 PM
#368   OXi4503 for Acute Myeloid Leukemia   OXi4503 (combretastatin A1-diphsphate; CA Penny Stocks 2.0 05/05/21 02:35:39 PM
#367   OXi4503: Pediatric AML   Pediatric AML is most common during Penny Stocks 2.0 05/05/21 02:34:50 PM
#366   AI/Blockchain: EdgePoint PointR, an acquisition made in November Penny Stocks 2.0 05/05/21 02:21:26 PM
#365   Taking Retail AI to Drug Manufacturing   Using it’s Amazon-Go-like Penny Stocks 2.0 05/05/21 02:21:18 PM
#364   Taking Retail AI to Drug Manufacturing   Using it’s Amazon-Go-like Penny Stocks 2.0 05/05/21 02:20:13 PM
#363   Market   Human labor costs represent the most expensive element Penny Stocks 2.0 05/05/21 02:19:44 PM
#362   Go-to-Market: IBM   The Company’s go-to-market plan is to execute Penny Stocks 2.0 05/05/21 02:18:22 PM
#361   $OTLC Incredible Podcast Anticipating $13 Billion in Revenues Penny Stocks 2.0 05/05/21 11:29:53 AM
#360   $OTLC MONSTROUS FDA GRANTED RARE PEDIATRIC CANCER COUPON Penny Stocks 2.0 05/05/21 11:20:28 AM
#359   $OTLC Huge FDA APPROVED OXi4503 has been awarded Penny Stocks 2.0 05/04/21 11:38:57 AM
#358   Big News out >> Oncotelic Joins Chopra Foundation Penny Stocks 2.0 05/04/21 07:37:48 AM
#357   Human Trial Success >> ONCOTELIC THERAPEUTICS, INC. ANNOUNCES Penny Stocks 2.0 05/03/21 11:48:49 AM
#356   Huge >> OXi4503 has been awarded Fast Track Penny Stocks 2.0 05/03/21 11:24:01 AM
#355   www.stockscores.com/chart.asp?TickerSymbol=OTLC&TimeRange=180&Interval=d& mick 05/02/21 08:29:50 PM
#354   Good presentation on Pulmoheal Usage. Hope Windlass is Birddogfishman 05/01/21 02:55:40 PM
#353   MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL Penny Stocks 2.0 04/30/21 01:20:26 PM
#352   OT-101 has demonstrated robust efficacy against pancreatic cancer, Penny Stocks 2.0 04/30/21 01:15:51 PM
#351   $OTLC Huge NEWS >> ONCOTELIC THERAPEUTICS, INC. Penny Stocks 2.0 04/30/21 01:09:05 PM
#350   $OTLC This is Huge, FDA GRANTS on Numerous Penny Stocks 2.0 04/30/21 12:49:29 PM
#349   $OTLC FDA Granted Pediatric Disease Designation for OXi-4503 Treatment Penny Stocks 2.0 04/30/21 10:33:57 AM
#348   FDA Granted Pediatric Disease Designation for OXi-4503 -Treatment of Penny Stocks 2.0 04/30/21 10:29:40 AM
#347   FDA granted CA4P rare pediatric designation for pediatric Penny Stocks 2.0 04/30/21 10:23:50 AM
#346   $OTLC Mateon has three major business segments: 1) Penny Stocks 2.0 04/30/21 10:19:30 AM
#345   $OTLC $4.00+ Price Litchfield Hills Research analyst report Penny Stocks 2.0 04/30/21 10:15:29 AM
#344   ONCOTELIC + WINDLAS Oncotelic and Windlas Biotech ready to Penny Stocks 2.0 04/30/21 10:04:58 AM
PostSubject
Consent Preferences